These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18626634)

  • 1. Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials.
    Arbouw ME; Movig KL; Guchelaar HJ; Poels PJ; van Vugt JP; Neef C; Egberts TC
    Eur J Clin Pharmacol; 2008 Oct; 64(10):1021-6. PubMed ID: 18626634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
    Zhao H; Ning Y; Cooper J; Refoios Camejo R; Ni X; Yi B; Parks D
    Adv Ther; 2019 Jun; 36(6):1252-1265. PubMed ID: 30963514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.
    Chung SJ; Kim JM; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    Expert Opin Pharmacother; 2015 May; 16(7):961-70. PubMed ID: 25846031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
    Zagmutt FJ; Tarrants ML
    Int J Neurosci; 2012 Jul; 122(7):345-53. PubMed ID: 22304415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
    Etminan M; Gill S; Samii A
    Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole and pramipexole, the new agonists.
    Hobson DE; Pourcher E; Martin WR
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole.
    Eggert K; Öhlwein C; Kassubek J; Wolz M; Kupsch A; Ceballos-Baumann A; Ehret R; Polzer U; Klostermann F; Schwarz J; Fuchs G; Jost W; Albert A; Haag A; Hermsen A; Lohmüller K; Kuhn K; Wangemann M; Oertel WH;
    Clin Neuropharmacol; 2014; 37(4):116-22. PubMed ID: 24992083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.
    Arbouw ME; Movig KL; Egberts TC; Poels PJ; van Vugt JP; Wessels JA; van der Straaten RJ; Neef C; Guchelaar HJ
    Eur J Clin Pharmacol; 2009 Dec; 65(12):1245-51. PubMed ID: 19669131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.
    Frucht S; Rogers JD; Greene PE; Gordon MF; Fahn S
    Neurology; 1999 Jun; 52(9):1908-10. PubMed ID: 10371546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 16. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.
    Quilici S; Abrams KR; Nicolas A; Martin M; Petit C; Lleu PL; Finnern HW
    Sleep Med; 2008 Oct; 9(7):715-26. PubMed ID: 18226947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.
    Pérez-Pérez J; Pagonabarraga J; Martínez-Horta S; Fernández-Bobadilla R; Sierra S; Pascual-Sedano B; Gironell A; Kulisevsky J
    Drugs Aging; 2015 May; 32(5):401-7. PubMed ID: 25941103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome.
    Kim J; Hartzema AG
    Sleep Med; 2018 Apr; 44():45-52. PubMed ID: 29530369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome.
    Sun Y; van Valkenhoef G; Morel T
    Curr Med Res Opin; 2014 Nov; 30(11):2267-78. PubMed ID: 25050588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.